ROYALTY PHARMA PLC- CL A (RPRX) Forecast, Price Target & Analyst Ratings

NASDAQ:RPRX • GB00BMVP7Y09

45.65 USD

-0.22 (-0.48%)

At close: Mar 13, 2026

45.64 USD

-0.01 (-0.02%)

After Hours: 3/13/2026, 8:00:02 PM

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ROYALTY PHARMA PLC- CL A (RPRX).

Consensus Price Target

Price Target

$52.39

+ 14.76% Upside

→ Price target details

Next Earnings Forecast

Earnings Estimate

Release Date: May 6, 2026
Period: Q1 / 2026
EPS Estimate: $1.23
Revenue Estimate: 1.463B

→ Full earnings forecast details

ChartMill Buy Consensus

Rating

83.75%

Weighted Analyst Rating Score

→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target

$52.39

Upside

+ 14.76%

From current price of $45.65 to mean target of $52.39, Based on 16 analyst forecasts

Low

$45.45

Median

$52.02

High

$64.05

Price Target Revisions

1 Month

7.86%

3 Months

13.89%

Price Target Summary

16 Wall Street analysts provided a forecast for the next 12 months for RPRX. The average price target is 52.39 USD. This implies a price increase of 14.76% is expected in the next year compared to the current price of 45.65.

The average price target has been revised upward by 13.89% in the past 3 months.

→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

Analyst Ratings History

Analyst Ratings Consensus

ChartMill Buy Consensus

83.75%

RPRX was analyzed by 16 analysts. The buy percentage consensus is at 84. So analysts seem to be very confident about RPRX.

In the previous month the buy percentage consensus was at a similar level.

RPRX was analyzed by 16 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.

→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

Date	Firm	Action	From → To
2026-01-27	Citigroup	Maintains	Buy -> Buy
2025-12-11	TD Cowen	Maintains	Buy -> Buy
2025-10-10	Morgan Stanley	Maintains	Overweight -> Overweight
2025-09-30	Goldman Sachs	Initiate	Buy
2025-07-22	Citigroup	Maintains	Buy -> Buy
2025-07-10	Morgan Stanley	Maintains	Overweight -> Overweight
2024-10-25	Citigroup	Maintains	Buy -> Buy
2024-08-14	Goldman Sachs	Maintains	Buy -> Buy
2024-07-11	Morgan Stanley	Maintains	Overweight -> Overweight
2024-06-03	UBS	Downgrade	Buy -> Neutral
2024-04-12	B of A Securities	Maintains	Buy -> Buy
2024-02-20	JP Morgan	Maintains	Overweight -> Overweight
2024-02-20	Goldman Sachs	Maintains	Buy -> Buy
2023-11-09	Morgan Stanley	Maintains	Overweight -> Overweight
2023-10-11	Morgan Stanley	Maintains	Overweight -> Overweight
2023-08-09	Morgan Stanley	Maintains	Overweight -> Overweight
2023-07-11	Morgan Stanley	Reiterate	Overweight -> Overweight
2023-05-10	Morgan Stanley	Maintains	Overweight
2023-04-10	Morgan Stanley	Maintains	Overweight
2023-02-16	UBS	Maintains	Buy
2022-12-06	Morgan Stanley	Maintains	Overweight
2022-11-09	Morgan Stanley	Maintains	Overweight
2022-10-18	JP Morgan	Maintains	Overweight
2022-08-08	Morgan Stanley	Maintains	Overweight
2022-07-14	Tigress Financial	Maintains	Buy

Next Earnings Forecast Details

Next Earnings Details

Release Date: May 6, 2026
Period: Q1 / 2026
EPS Estimate: $1.23
Revenue Estimate: 1.463B
Revenue Q2Q: 74.37%
EPS Q2Q: 89.88%
Number of Analysts: 6

Next Earnings Revisions

Revenue (1 Month)

96.30%

Revenue (3 Months)

93.91%

EPS (1 Month)

5.22%

EPS (3 Months)

4.31%

Next Earnings Summary

RPRX is expected to report earnings on 5/6/2026. The consensus EPS estimate for the next earnings is 1.23 USD and the consensus revenue estimate is 1.46B USD.

The next earnings revenue estimate has been revised upward by 93.91% in the past 3 months. Upward revisions are a positive sign and indicate that analysts are more optimistic about the next earnings compared to 3 months ago.

→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033
Revenue YoY % growth	2.355B 5.25%	2.264B -3.86%	2.378B 5.06%	3.289B 38.30%	3.447B 4.80%	3.68B 6.76%	4.678B 27.12%	5.093B 8.87%	5.342B 4.89%	5.662B 5.99%	5.832B 3.00%
EBITDA YoY % growth	N/A 7.26%	N/A -6.92%	N/A 6.89%	3.164B 13.94%	3.384B 6.95%	3.809B 12.56%	4.313B 13.23%	4.712B 9.25%	4.974B 5.56%	5.326B 7.08%	5.489B 3.06%
EBIT YoY % growth	1.492B 61.68%	1.292B -13.38%	1.56B 20.66%	3.005B 92.69%	3.05B 1.50%	3.067B 0.56%	2.5B -18.49%	2.797B 11.88%	2.882B 3.04%	3.035B 5.31%	3.127B 3.03%
Operating Margin	63.37%	57.10%	65.58%	91.37%	88.48%	83.34%	53.44%	54.92%	53.95%	53.60%	53.62%
EPS YoY % growth	4.38 19.35%	4.10 -6.39%	4.43 8.05%	5.17 16.65%	5.54 7.15%	6.20 12.06%	7.18 15.73%	7.86 9.52%	8.25 4.93%	8.76 6.18%	N/A

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

	Q1 / 26	Q2 / 26	Q3 / 26	Q4 / 26
EPS Q2Q % growth	1.23 89.88%	1.31 14.53%	1.30 10.72%	1.63 11.02%
Revenue Q2Q % growth	1.463B 74.37%	723.11M -0.54%	826.52M 1.54%	1.007B 61.90%
EBITDA Q2Q % growth	1.484B 106.82%	665.76M 5.66%	775.57M 9.28%	965.94M 30.94%
EBIT Q2Q % growth	1.516B 183.80%	656.38M 212.86%	650.48M 52.28%	N/A

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year

11.89%

EPS Next 5 Year

12.16%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year

5.20%

Revenue Next 5 Year

10.01%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year

10.82%

EBIT Next 5 Year

10.98%

→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

ROYALTY PHARMA PLC- CL A / RPRX Forecast FAQ

What do analysts expect the price target to be for ROYALTY PHARMA PLC- CL A (RPRX)?

16 analysts have analysed RPRX and the average price target is 52.39 USD. This implies a price increase of 14.76% is expected in the next year compared to the current price of 45.65.

What is the next earnings date for RPRX stock?

ROYALTY PHARMA PLC- CL A (RPRX) will report earnings on 2026-05-06.

What are the consensus estimates for ROYALTY PHARMA PLC- CL A (RPRX) next earnings?

The consensus EPS estimate for the next earnings of ROYALTY PHARMA PLC- CL A (RPRX) is 1.23 USD and the consensus revenue estimate is 1.46B USD.

How many analysts have analysed ROYALTY PHARMA PLC- CL A (RPRX)?

The number of analysts covering ROYALTY PHARMA PLC- CL A (RPRX) is 16.

Analyst forecast overview

Forecast Snapshot